Le Lézard

News by subject: TRI

1 2 3 4 5 6 7 8 9 10

Today

15:35
ONCOtherapeutics and Dr. James Berenson published promising new data demonstrating that ruxolitinib (RUX), an oral JAK1/2 inhibitor, with only steroids is well tolerated and shows promising efficacy for treating heavily previously treated MM...

15:16
Saluda Medical Pty Limited ("Saluda Medical"), the market leader in the development of closed-loop spinal cord stimulation for the treatment of chronic pain, announced scientific highlights from the 2021 North American Neuromodulation Society (NANS...

10:15
Tampa General Hospital is one of the first sites in the nation to study whether a new technology can safely and effectively destroy tumors without using an invasive procedure....

10:04
Not intended for UK-based media Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced an update...

09:08
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the peer-reviewed publication of a preclinical study in the journal Stem Cell and Research Therapy. The study,...

09:00
Findings from a Phase 3 study of VM202 (the active ingredient in Engensis) for the treatment of patients with painful diabetic peripheral neuropathy (DPN) have just been published in Clinical and Translational Science:...

08:38
Hoth Therapeutics, Inc. , a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the...

08:00
Seneca Biopharma, Inc. , a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today announced preliminary, top-line results of the Company's placebo controlled Phase 2 stroke study (non-GCP) that...

08:00
RenovoRx, an innovator in targeted cancer therapy, today announced two research studies were presented at the 2021 ASCO Gastrointestinal Cancers Symposium that further advance the science of pancreatic cancer treatment. In one presentation,...

07:30
MindMed (NEO: MMED), , (DE: MMQ), a leading psychedelic medicine biotech company, announced today the start of the first ever clinical trial measuring and evaluating MDMA and LSD used in combination in the human body. The trial will be conducted at...

07:30
Tris Pharma, Inc. ("Tris"), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related...

07:00
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. ("Bausch Health"), today announced that two poster presentations will feature data on the new Bausch + Lomb INFUSEtm silicone hydrogel (SiHy) daily disposable...

02:13
Calliditas Therapeutics AB (publ) ("Calliditas") today announced it will provide information on the near-term clinical development plans for setanaxib in primary biliary cholangitis (PBC) and oncology. It will also present additional data from the...

00:53
On January 15, Jemincare Group, a Chinese pharmaceutical company, announced that it has initiated the phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody (JMB2002). Preclinical studies of JMB2002 including pharmacology and toxicity were...


19 january 2021

12:34
ARUP Laboratories, a major provider of COVID-19 molecular diagnostic testing in Utah and nationwide, today announced that it is sequencing variants of SARS-CoV-2 in specimens positive for COVID-19 to enable detection of the more contagious "United...

10:00
Bioclinica, an integrated solutions provider of clinical life science and technology expertise, today announced a new product to support redaction of sensitive patient information from videos, photos, and PDFs in clinical trials. The addition of...

09:45
ObvioHealth, a global virtual research organization (VRO), and GI Alliance, one of the nation's largest independent gastroenterology services organization, jointly announce a new partnership to create better clinical trial experiences through the use...

09:30
Therapeutic Solutions International, Inc., , reported positive animal data in the 4T1 breast cancer model using its clinically tested StemVacstm cellular immunotherapy.  In a series of experiments, it was demonstrated that StemVacstm administration...

09:07
Advarra, the market leader in regulatory review solutions and clinical site technologies, announces the Gene Therapy Readytm site network, a comprehensive collective of clinical research sites ready to conduct clinical trials involving genetically...

09:00
Pharm-Olam, a global mid-sized clinical research organization (CRO), has been selected by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to lead and...

09:00
Menon Biosensors, Inc. ("Menon" or the "Company"), a distributive technology portfolio company, announced today that trials will advance on its proprietary Molecular Mirrortm platform technology in collaboration with the University of California San...

09:00
Withings, early pioneers of the connected health revolution, joins an historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research....

09:00
Renovia Inc. ("Renovia"), a women-led company that develops digital therapeutics for female pelvic floor disorders, today announced the appointment of Eileen Maus in Q4 2020 as the company's president and CEO. Under her leadership, Renovia completed...

08:30
AcelRx Pharmaceuticals, Inc. , (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initiated study with University...

08:00
Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0184, an activin receptor-like kinase 2 (ALK2) and...

08:00
A new study in Mayo Clinic Proceedings entitled "Aseptic Stethoscope Barriers Prevent C. difficile Transmission In Vitro"2 finds that aseptic disk covers from AseptiScope, available now commercially in the company's flagship product, The DiskCover...

08:00
Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, announced today that it will host a Key Opinion Leader (KOL) symposium and pipeline update on...

08:00
The inflammation COVID-19 patients suffer during and post-COVID-19 infection (AKA "Post-COVID Syndrome") will be one of many focuses of a new Research & Development laboratory recently launched at the University of Florida Sid Martin Innovate...

07:45
Creative Medical Technology Holdings announced positive data and filing of a patent application covering the use of ImmCelz® in prevention and regression of type 1 diabetes. ...

07:30
BioEclipse Therapeuticstm (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the initiation of patient enrollment at the HonorHealth...

07:30
Accuray Incorporated announced today that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelerated partial breast irradiation...

07:07
The leader in site specific bioconjugation and DAR (drug to antibody ratio) optimization in antibody drug conjugates (ADCs) and protein therapeutics, has created a novel class of bispecific antibodies that have the ability to be labeled and...

07:00
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. ("Bausch Health" or the "Company"), and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class...

07:00
Scopus BioPharma Inc.  today announced the completion of clinical lot manufacturing fulfilling the requirements for the planned Phase 1 clinical trial for non-Hodgkin's lymphoma.  This is a key milestone to enable finalization of the investigational...

07:00
Nevro Corp. , a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced  the results from data presentations at NANS supporting the use of HF10® therapy for patients with...

06:30
Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, today announced positive results from a study using MI GPSaitm (Genomic Prevalence Score) an...

03:15
Vera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP. Other investors...

03:00
Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent inactivated coxsackievirus B (CVB) vaccine it developed and manufactured for Provention Bio in less...

03:00
ConserV Bioscience Limited ("ConserV"), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases and Lawrence Livermore National Laboratory ("LLNL") have agreed to collaborate...


18 january 2021

18:45
An article published in Experimental Biology and Medicine (Volume 246, Issue 2, January, 2021) (https://journals.sagepub.com/doi/pdf/10.1177/1535370220963755) reports a cell replacement therapy for blindness caused by loss of photoreceptors. The...

17:10
Translational Genomics Group (Dr. Artero's Lab), a Spanish research laboratory affiliated to the University of Valencia (UVEG) and INCLIVA Biomedical Research Institute, is pioneer in discovering therapeutic targets and innovative drug candidates for...

09:00
Biohaven Pharmaceutical Holding Company Ltd. today announced that it has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as a symptomatic treatment in mild-to-moderate...

08:14
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient dosed in an investigator-initiated, randomized phase II, open-label clinical trial for its antiviral alisporivir (Debio 025). The study will be...

06:00
- The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination - The medicine,...

06:00
Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines...

03:00
- Pre-clinical in vitro research from the Mondor Institute of Biomedical Research (INSERM U955) has shown evidence for the effectiveness of alisporivir against the replication of SARS-COV-2 (COVID-19)1 - A randomized, investigator-initiated, phase...

02:11
Genkyotex SA, a subsidiary of Calliditas Therapeutics AB (publ) ("Calliditas") , today announced positive Phase 1 data demonstrating a favorable safety and pharmacokinetic profile of high-dose setanaxib, Genkyotex's lead asset. The Phase 1 study...


17 january 2021

19:00
Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced dose administration for the first patient in a Phase 2a clinical study of the company's...

05:00
Steba biotech, pioneering developer of the IMmune Photo Activate Cancer Treatment (ImPACT), announced today...


15 january 2021

14:00
Dr. Paul E. Love, an NIH investigator from Bethesda, Maryland, conducts research that is testing if human T Cell Receptor (TCR) signaling components and TCR signal modifying proteins can serve as targets for immunotherapy. This research, which could...

1 2 3 4 5 6 7 8 9 10